Lonza Group is a Swiss chemicals and biotechnology company, headquartered in Basel. The firm provides a number of products and services to the pharmaceutical and life science industries, including organic fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities and chemicals, detection systems and services for the bioscience sector. Wikipedia.
News Article | May 8, 2017
— Global Antimicrobial Additives Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are Basf, The Dow Chemical Company, Clariant, A. Schulman, Steritouch, Polyone, Sanitized, Microban International, Biocote, Lonza Group, Biosafe, Milliken Chemical, Nolla Antimicrobial, Rtp Company, Addmaster Limited, Plastics Color Corporation, Nanobiomatters, Agion Technologies, Bayer Materialscience, Ciba Specialty Chemicals Corporation, Teknor Apex, Troy Corporation, Momentive Performance Materials, Arkema Group, Parx Plastic Bv (Netherlands), Porex Corporation, Americhem in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • Silver • Copper • Zinc Split by applications, this report focuses on sales, market share and growth rate of Antimicrobial Additives in each application, can be divided into • Packaging • Food & Beverage • Construction • Automotive Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/501897 Table of Content: 1 Antimicrobial Additives Market Overview 2 Global Antimicrobial Additives Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Antimicrobial Additives Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Antimicrobial Additives Manufacturers Profiles/Analysis 5 North America Antimicrobial Additives Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Antimicrobial Additives Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Antimicrobial Additives Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Antimicrobial Additives Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Antimicrobial Additives Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Antimicrobial Additives Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Antimicrobial Additives Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/501897 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-antimicrobial-additives-market-report
News Article | April 25, 2017
Global Cosmetic Preservatives market is estimated to be $258.4 million in 2015 with a CAGR of 6.0% is poised to reach $390.8 million by 2022.Pune , India - April 25, 2017 /MarketersMedia/ — Cosmetic Preservatives Industry Description According to Stratistics MRC, the Global Cosmetic Preservatives market is estimated to be $258.4 million in 2015 with a CAGR of 6.0% is poised to reach $390.8 million by 2022. Increasing requirement for paraben free preservatives has poised the market growth. The market is further driven by factors such as growing shelf life advancements, enhancing living standards and rising demand for synthetic and natural preservatives. However, skin infections and stringent government regulations are some of the factors limiting the market. Furthermore, rising demand in Asia Pacific region will offer great investment opportunities for players in the market. Synthetic preservatives segment accounted for largest market share across the globe. Moreover, accessibility of raw materials at reasonable price is one of a key trend fostering this segment. By geography, North America dominated the global market in terms of revenue owing to succeeding demand for anti-aging products such as creams and moisturizers. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/674243-cosmetic-preservatives-global-market-outlook-2016-2022 Some of the key players in this market include Chemipol S.A, Salicylates & Chemicals Pvt. Ltd, The DOW Chemical Company, Symrise AG, Lonza Group Ltd. , Ashland Inc., Brenntag AG, Clariant AG, MnM View and Akema Fine Chemicals. Product Covered: • Synthetic Preservatives • Natural Preservatives Application Covered: • Mouthwash & Toothpaste • Soaps, Shower Cleansers & Shaving Gels • Lotions, Facemasks, Sunscreens & Scrubs • Face Powder & Powder Compacts • Shampoo & Conditioners • Other Applications Leave a Query @ https://www.wiseguyreports.com/enquiry/674243-cosmetic-preservatives-global-market-outlook-2016-2022 Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=674243 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) Contact Info:Name: NORAH TRENTEmail: email@example.comOrganization: WISE GUY RESEARCH CONSULTANTS PVT LTDAddress: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028Phone: +91 841 198 5042Source URL: http://marketersmedia.com/cosmetic-preservatives-market-2017-global-analysis-opportunities-and-forecast-to-2022/190047For more information, please visit https://www.wiseguyreports.com/sample-request/674243-cosmetic-preservatives-global-market-outlook-2016-2022Source: MarketersMediaRelease ID: 190047
News Article | May 3, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Mycoplasma Testing Market Analysis By Product, By Technology (PCR, ELISA, Direct Assay, Microbial Culture Techniques), By Application (Cell Line, Virus, & End of Production Cells Testing), By End-use, And Segment Forecasts, 2014 - 2025" report to their offering. The global mycoplasma testing market is expected to reach a value of USD 1.4 billion by 2025 With growing R&D investments in the field of life sciences, the demand for mycoplasma testing products are anticipated to rise in the near future. Huge opportunities in the life sciences segment are spurring the market growth. Hence, a large amount of investment is being made in the biotechnology and pharmaceutical industries with rising level of healthcare spending across the globe. This is expected to trigger high growth of mycoplasma testing market. Investment in R&D activities by pharmaceutical and biotechnology companies is increasingly being supported by the government. Researches involving drug discovery and development, receive funding from the governmental bodies to a great extent. Moreover, governmental initiatives in the form of awareness campaigns for chronic diseases such as cancer are also encouraging research-based activities. Thus, the aforementioned factors are expected to drive the market growth. Mycoplasma contamination of cell culture is a growing concern for most of the research scientists for decades. Mycoplasma infection arises majorly from laboratory workers as human mycoplasma contamination occurs at a faster rate. In order to combat further contamination, mycoplasma tests are being conducted, which is expected to increase the demand of the related products. Some of the key players are Merck KGaA; Sigma-Aldrich Co.; Thermo Fisher Scientific; Lonza Group Ltd.; Charles River Laboratories International, Inc.; PromoCell GmbH; and Bionique Testing Laboratories, Inc. For more information about this report visit http://www.researchandmarkets.com/research/mfs23g/mycoplasma
News Article | February 28, 2017
Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Healthcare Contract Manufacturing Services Market Analysis: Service Types, Growth Trends, and Forecast to 2020, New Research by iHealthcareAnalyst, Inc. Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 Maryland Heights, MO, February 28, 2017 --( Browse Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 report at https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/ Pharmaceutical and medical devices contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) serves the pharmaceutical and medical device industry and provides clients with comprehensive services from drug or device development, through manufacture of pharmaceutical drugs, medical equipment or devices and parts. The pharmaceutical and medical device companies are outsourcing their drugs and devices manufacturing to concentrate on R&D and marketing of their products by minimizing the time invested in manufacturing practices. The global healthcare contract manufacturing services market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market based on service type (pharmaceutical manufacturing of API, FDF, drug formulations; and device manufacturing of medical equipment, materials, parts, electronic items), and forecasts growth trends (CAGR% - 2016 to 2020). The global healthcare contract manufacturing services market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global healthcare contract manufacturing services market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global healthcare contract manufacturing services market and included in this report are Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: firstname.lastname@example.org Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 28, 2017 --( PR.com )-- The global healthcare contract manufacturing services market to reach nearly USD 230 Billion in 2020, at a CAGR of 11.2% from 2016 to 2020, majorly due to lower cost of production. The market for contract manufacturing shows tremendous potential due to growth in the medical device industry, growing regulatory concerns and increasing demand from emerging countries.Browse Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 report at https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/Pharmaceutical and medical devices contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) serves the pharmaceutical and medical device industry and provides clients with comprehensive services from drug or device development, through manufacture of pharmaceutical drugs, medical equipment or devices and parts. The pharmaceutical and medical device companies are outsourcing their drugs and devices manufacturing to concentrate on R&D and marketing of their products by minimizing the time invested in manufacturing practices.The global healthcare contract manufacturing services market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market based on service type (pharmaceutical manufacturing of API, FDF, drug formulations; and device manufacturing of medical equipment, materials, parts, electronic items), and forecasts growth trends (CAGR% - 2016 to 2020). The global healthcare contract manufacturing services market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global healthcare contract manufacturing services market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global healthcare contract manufacturing services market and included in this report are Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: email@example.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
News Article | February 27, 2017
Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility - The large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture with an initial investment of around CHF 290 million (€ 270 million) shared equally between Sanofi and Lonza - - The strategic partnership leverages Lonza's expertise in large-scale mammalian cell culture facilities alongside Sanofi's strength in developing and launching biologics based treatments to address patient needs - Paris, France and Basel, Switzerland - February 27, 2017 - Sanofi and Lonza announced today that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The strategic partnership in the form of a joint venture combines the strong biologics development pipeline of Sanofi with the expertise of Lonza to design, construct, start-up and operate a state-of-the-art large-scale mammalian cell culture facility. The initial investment will be around CHF 290 million (€ 270 million), to be split equally between each company. The initial phase of the facility will commence construction in 2017, pending necessary regulatory approvals, and is expected to be fully operational by 2020. Lonza has previously built and licensed three similar facilities in the U.S. and Singapore. "In addition to the investments we are making in building our own internal production capabilities, the joint venture between Sanofi and Lonza emphasizes our commitment to provide access for patients to high quality therapeutic monoclonal antibodies," said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi. "Approximately sixty percent of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology. Lonza is a highly experienced partner in this field and the capabilities which this joint venture will create are critical to meeting our patients' needs for these important therapies." "By entering into this long-term strategic relationship we have developed a tailor-made business model that best fits both Sanofi's and Lonza's requirements. It provides to Sanofi dedicated capacity, which allows for a clear win-win situation for all participants," said Marc Funk, COO Pharma & Biotech, Lonza. "As part of our strategic roadmap, we will develop further innovative business models based on the requirements of our customers. We intend to address these long-term market needs by establishing a state-of-the-art strategic biologics manufacturing platform. The strategic partnership with Sanofi represents the first module in this undertaking; and we are convinced that with this future-oriented approach, we can serve additional customers." The partnership provides both Sanofi and Lonza with substantial flexibility in an innovative setup: The strategic partnership enables Sanofi to react quickly to fluctuations in demand in a short timeframe, reinforcing their capability to launch high-quality, next generation biologic medicines and ensure consistent access for patients. It also provides Lonza with needed capacities to respond to growing manufacturing demands for large-scale mammalian cell culture based therapeutic proteins, therefore allowing Lonza to better serve its customers. By adding flexibility in this way, this model will help to optimize biologics production capacity across the whole industry. About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). About Lonza Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com. Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Lonza Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.  Culture of mammalian cells is fundamental to the manufacture of complex biopharmaceutical products. Biopharmaceutical products produced in mammalian cells include for example enzymes, recombinant vaccines, immunobiologicals (e.g. monoclonal antibodies, interleukins, lymphokines), and anticancer agents.
News Article | February 17, 2017
Sarasota, FL, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Anti-Microbial Coatings Market (Antimicrobial Powder Coatings and Surface Modifications & Coatings) for Indoor Air Quality, Medical/Healthcare, Mold Remediation, Textiles, Construction, Food and Other Applications: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022”. According to the report, the global anti-microbial coatings market accounted for USD 2.74 Billion in 2016 and is expected to reach USD 5.30 Billion by 2022, growing at a CAGR of around 11.7% between 2017 and 2022. The global anti-microbial coatings market is expected to witness significant growth over the forecast period on account of the increasing demand from the healthcare sector. Anti-microbial coatings are used to prevent the growth of microorganisms on the surface. It either destroys the microorganism or prevents its growth. The stringent regulations on the healthcare sector to use anti-microbial coatings are expected to be a major driver for the anti-microbial coatings market within the forecast period. Demand from high-end commercial and residential construction projects is also expected to aid the growth of the anti-microbial coatings market in the coming years. However, the quality regulations and health issues connected to the use of silver are expected to restrain the growth of anti-microbial coatings market within the forecast period. Technological advancements in order to improve efficiency and quality are expected to open new avenues of opportunities in the coming years. Browse through 23 Market Tables and 28 Figures spread through 167 Pages and in-depth TOC on “Global Anti-Microbial Coatings Market: By Type, Application, Size, Share, Trends, Analysis, Segment and Forecast 2016 – 2022”. Among the products, surface modification & coatings segment accounted for the largest market share in 2016 and is expected to grow at a significant rate. These are continuously being developed for certain surfaces to combat the presence of E. Coli and other bacteria. The anti-microbial powder coatings segment is expected to witness significant growth and this can be attributed to its applications in medical care, sanitation, steel furniture industry and domestic appliances. Indoor air quality was studied as the most dominant application segment in 2016 accounting for the largest share of the global anti-microbial coatings market. Initiatives are being taken by the regulatory bodies in order to educate the people about indoor air quality is expected to drive the demand for anti-microbial coatings for indoor air quality improvement within the forecast period. Medical/Healthcare segment accounted for the second largest market share of anti-microbial coatings in 2016 and is expected to grow in light of stringent regulations mandating the use of anti-microbial coatings on medical devices, equipment etc. Mole remediation segment is also expected to witness significant growth owing to the regulations to prevent the use of VOCs. Browse the full "Anti-Microbial Coatings Market (Antimicrobial Powder Coatings and Surface Modifications & Coatings) for Indoor Air Quality, Medical/Healthcare, Mold Remediation, Textiles, Construction, Food and Other Applications: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022" report at https://www.zionmarketresearch.com/report/anti-microbial-coatings-market North America accounted for the largest share of anti-microbial coatings market across the globe. North America is also expected to be the fastest-growing region for anti-microbial coatings market within the forecast period. Stringent regulations on the healthcare industry to adopt anti-microbial coatings are expected to be one of the major drivers for the market in this region. Improving living standards coupled with increased spending on healthcare have also contributed positively towards the growth of anti-microbial coatings market in North America. Europe anti-microbial coatings market is expected to witness significant gains within the forecast period owing to the stringent regulations mandating the use of anti-microbial coatings. The growth of the food industry in the region and other end-use industries is also expected to aid the growth of anti-microbial coatings market in Europe. Rising consumer awareness and applications such as indoor air quality are also spurring the growth of anti-microbial coatings market in the region. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/anti-microbial-coatings-market Asia Pacific is expected to register significant growth within the forecast period for anti-microbial coatings market. This can be attributed to the increasing demand from countries like China and India. The large population and rising construction industry in the region are expected to be the major drivers for anti-microbial coatings market in Asia-Pacific. The growing medical tourism in India is also expected to augment the demand from the healthcare sector. In addition, the rapidly growing food industry in the region is also expected to contribute positively towards the growth of Asia Pacific anti-microbial coatings market. Latin America is expected to witness moderate growth within the forecast period. The demand for anti-microbial coatings from the healthcare sector is expected to be the major driver for the market in Latin America. Rising health awareness is also expected to boost the growth of anti-microbial coatings market in the future. The Middle East and Africa is expected to witness sluggish growth for anti-microbial coatings market within the forecast period. The rising construction and infrastructure redevelopment activities in the region are expected to drive the demand for anti-microbial coatings in the region. The key players operating in the global anti-microbial coatings market are Microban International Ltd., Cupron Inc., Specialty Coatings Company Inc., AK Coatings Inc., HaloSource Inc., Dow Microbial Control, AcryMed Inc., Alistagen Corporation, AEGIS Environments, Sciessent LLC, BBJ Environmental Technologies Inc., EnviroCare Corporation, Fosters Products Corporation, Fiberlock Technologies Inc., Sports Coatings, Lonza Group Ltd., Semprus Biosciences Corporation, Troy Corporation and Sureshield Coatings Company. For more inquiry contact our sales team @ firstname.lastname@example.org This report segments the global anti-microbial coatings market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
News Article | February 23, 2017
Research and Markets has announced the addition of the "Global Pharmaceutical Fine Chemicals Market Analysis & Trends - Industry Forecast to 2025" report to their offering. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. Some of the prominent trends that the market is witnessing include companies producing fine chemicals are making efforts towards development of efficient products, technological advancements in production procedures, expansion in the pharmaceutical industry in emerging regions and growth opportunities/investment opportunities. Based on Chemicals the market is categorized into big molecules and small molecules. Based on Type of Drug the market is categorized into non proprietary drugs and poprietary drugs. As per Therapeutic Use the market is segmented into respiratory gastrointestinal, mucoskeletal, diabetes, metabolic system, cardiovascular, infectious diseases, neurological, oncological and other therapeutic uses. Report Highlights: - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments Key Topics Covered: 1 Market Outline 2 Executive Summary 3 Market Overview 3.1 Current Trends 3.1.1 Companies Producing Fine Chemicals are Making Efforts towards Development of Efficient Products 3.1.2 Technological Advancements In Production Procedures 3.1.3 Expansion in the Pharmaceutical Industry in Emerging Regions 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 4 Pharmaceutical Fine Chemicals Market, By Chemical 4.1 Big Molecules 4.2 Small Molecules 5 Pharmaceutical Fine Chemicals Market, By Type of Drug 5.1 Non Proprietary Drugs 5.2 Poprietary Drugs 6 Pharmaceutical Fine Chemicals Market, By Therapeutic Use 6.1 Respiratory 6.2 Gastrointestinal 6.3 Mucoskeletal 6.4 Diabetes 6.5 Metabolic System 6.6 Cardiovascular 6.7 Infectious Diseases 6.8 Neurological 6.9 Oncological 6.10 Other Therapeutic Uses 7 Pharmaceutical Fine Chemicals Market, By Geography 8 Key Player Activities 8.1 Mergers & Acquisitions 8.2 Partnerships, Joint Venture's, Collaborations and Agreements 8.3 Product Launch & Expansions 8.4 Other Activities 9 Leading Companies 9.1 Abbott 9.2 Akzo Nobel N.V 9.3 Albemarle Corporation 9.4 AstraZeneca 9.5 BASF SE 9.6 Boehringer Ingelheim GmbH 9.7 Clariant AG 9.8 Eastman Chemical Company 9.9 Evonik Industries 9.10 GlaxoSmithKlein 9.11 Lonza Group Ltd 9.12 Merck and co. 9.13 Roche 9.14 Royal DSM N.V. 9.15 The Dow Chemical Company For more information about this report visit http://www.researchandmarkets.com/research/4t3ktc/global
News Article | February 16, 2017
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity, have entered into a strategic manufacturing agreement. Under the terms of the agreement, Lonza will produce an Anc80-AAV-based gene therapy product for Selecta’s proprietary program for the treatment of Methylmalonic Acidemia (MMA), a rare inborn error of metabolism, and may in the future produce other Anc80-based products for which Selecta holds exclusive options. This relationship will leverage Lonza’s expertise in the development of robust and industry-scale manufacturing platforms for viral-based products. Data shows that Anc80-AAV, an in silico-designed synthetic gene therapy vector, has the potential to provide superior gene expression levels in retina, liver, muscle, cochlea’s outer hair cells and other tissue targets in preclinical studies, as well as reduced cross-reactivity as compared to naturally occurring adeno-associated viral vectors (AAVs) that are currently in clinical development. “This agreement with Selecta Biosciences continues to demonstrate Lonza’s leadership position in the cell and gene therapy space,” said Andreas Weiler, Ph.D., Head of Emerging Technologies Business Unit for Lonza’s Pharma&Biotech segment. “Lonza will utilize our extensive cGMP manufacturing knowledge and world-class quality systems to help Selecta Biosciences develop promising novel therapeutics for patients impacted by MMA and other devastating diseases.” “We at Selecta are focused on combining novel and proprietary viral vectors with our immune tolerance Synthetic Vaccine Particles (SVP™) to enable the first non-immunogenic gene therapies, providing the potential for repeat dosing,” said Werner Cautreels, Ph.D., Selecta’s president, CEO and chairman. “We view Lonza – one of the industry’s largest contract manufacturers of biologics and a leading supplier in gene therapy – as an ideal partner. They already have invested in developing various expression technologies, and they share our excitement about Anc80. We look forward to working with them to bring the first Anc80-based program into the clinic as a potential treatment for patients afflicted with MMA.” MMA is an inborn error of metabolism that, according to the National Institutes of Health (NIH), affects an estimated one in 25,000 to 48,000 individuals globally. MMA patients are unable to process certain proteins and fats, leading to the accumulation of toxic metabolites. Symptoms start to develop in early childhood and, despite strict diet, patients suffer from a wide range of disease-related complications such as pancreatitis, strokes and chronic kidney failure. Selecta exclusively licensed Anc80 for MMA from Massachusetts Eye and Ear® (MEE) in May 2016. Under the license agreement, Selecta also has the exclusive option to develop gene therapies using Anc80 for additional pre-defined lysosomal storage, genetic muscular and genetic metabolic diseases. Selecta intends to combine Anc80 with recently discovered transgenes and Selecta’s SVP-Rapamycin to create a novel gene therapy candidate for MMA. This candidate is intended to a) enable the treatment of patients with and without pre-existing anti-AAV antibodies; b) prevent cellular immune responses that often reduce the expression levels of gene therapies; and c) provide the ability to administer repeat gene therapy doses to achieve sufficient levels of methylmalonyl-CoA mutase (MUT), the enzyme that MMA patients are lacking. To advance the MMA program, Selecta entered into a Collaborative Research and Development Agreement (CRADA) with MEE and the National Human Genome Research Institute, NIH, in 2016. Principal investigators in this CRADA initiative are Charles Venditti, MD, PhD, Senior Investigator and Head, Organic Acid Research Section, Medical Genomics and Metabolic Genetics Branch and Luk Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at MEE and an Assistant Professor at Harvard Medical School. A physician-scientist specializing in the study of inborn errors of metabolism including MMA, Dr. Venditti and his group have published several studies showing the effectiveness of gene therapy as a treatment for MMA in mice. Dr. Vandenberghe from MEE is the inventor of Anc80. Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications. Selecta is applying its proprietary Synthetic Vaccine Particles (SVP™) to a range of therapeutic areas in which immunogenicity is a key challenge. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat chronic refractory gout patients and reduce their debilitating symptoms, including flares and inflammatory arthritis. Further, Selecta’s two proprietary gene therapy product candidates have the unique potential to enable repeat administration, allowing for dose adjustment in patients and maintenance of therapeutic activity over time. The company is seeking to expand the use of its SVP platform in other areas, such as immuno-oncology, allergies, autoimmune diseases and vaccines. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com. Additional Lonza Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release. Selecta Biosciences, Inc. Disclaimer Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the development of its pipeline, the ability of the company’s SVP platform, including SVP-Rapamycin, to mitigate immune response and create better therapeutic outcomes, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, whether the company’s proprietary gene therapy product candidates will enable repeat administration, allow for dose adjustment in patients or maintain therapeutic activity over time, the sufficiency of the company’s cash, cash equivalents, investments, and restricted cash and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the unproven approach of the company’s SVP technology, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, substantial fluctuation in the price of its common stock, a significant portion of the company’s total outstanding shares have recently become eligible to be sold into the market, and other important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2016, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.
News Article | February 23, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Healthcare Contract Manufacturing Outsourcing (CMO) Market - Forecasts from 2016 to 2021" report to their offering. Global Healthcare Contract Manufacturing Outsourcing (CMO) Market is projected to grow at a compound annual growth rate of 10.28% over the forecast period to reach US$205.104 billion by 2021, from US$114.018 billion in 2015. Rising research and development cost of drugs is driving the healthcare CMO market. Industry and government regulations have forced enterprises to outsource manufacturing operations to the third party to remain competitive and enhance business process efficiency. Increasing investment in the healthcare sector has also provided the necessary impetus to the market. The emergence of developing economies of China and India as favorable manufacturing markets is shifting the balance towards these countries as compared to Europe, which has dominated the CMO market. The first section of the report deals with detailed research methodology for calculating market size and forecasts, secondary data sources used and the primary inputs which were taken for data validation. This section also outlines various segmentations which have been covered as part of the report. Next section provides comprehensive market dynamics through an overview section along with growth drivers, challenges, and opportunities which exist in the current market. This section of the report also provides supplier and industry outlook as a whole; key industry, global and regional regulations which are determining the product specifications and a brief technological aspect of Healthcare CMO solutions. Complete industry analysis has also been covered by Porter's five forces model as a part of this report section. Thirdly, Healthcare CMO market has been segmented on the basis of services and geography. Under different services, pharmaceutical CMO, and medical device CMO have been covered. By pharmaceutical CMO this market has been segmented into Active Pharmaceutical Ingredients (API) Manufacturing, Final Dose Formulation (FDF) Manufacturing and Packaging services, while under medical device CMO Design Outsourcing, Device Manufacturing and Final Goods Assembly have been covered through detailed market analysis and forecast for the next five years. Important regions for vendors in terms of market size is covered through detailed geographical segmentation. Geographical regions covered as a part of this section are Americas (North and South America), Europe Middle East and Africa and Asia Pacific. Finally, competitive intelligence section deals with major players in the market, their market shares, growth strategies, products, financials, and recent investments among others. Key industry players profiled as part of this section are Jubilant Life Sciences Limited, Pfizer CentreOne, Lonza Group, Recipharm AB, Catalent and DPx Holdings along with several other players. For more information about this report visit http://www.researchandmarkets.com/research/z4vndz/healthcare
News Article | February 16, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021" report to their offering. The top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between 2016 and 2021. Growth in the biopharmaceutical industry, increase in R&D spending, rising demand for vaccine production, and technological advancements form important growth drivers for this market during the forecast period. The rising opportunities in emerging market and increasing pharmaceutical outsourcing provide significant growth opportunities for players operating in the top 10 bioprocess technology market. The report provides an overall understanding of the global top 10 bioprocess technology market. It segments the global market on the basis of type and region. On the basis of type, the market is segmented into cell culture, cell expansion, cell counting, cell line development, flow cytometry, single-use bioprocessing, biologics safety testing, virus filtration, tangential flow filtration, and pyrogen testing. In 2016, the cell culture segment is expected to account for the largest share of the global top 10 bioprocess technology market. The largest share of this segment is primarily attributed to the repeated purchase of consumables as compared to equipment and increase in funding for cell-based research. The major players in top 10 bioprocess technology market include GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Lonza Group AG (Switzerland), Merck Millipore (Germany), Sartorius Stedim Biotech S.A (France), Corning, Inc. (U.S.), Bio-Rad Laboratories (U.S.), and Charles River Laboratories (U.S.). For more information about this report visit http://www.researchandmarkets.com/research/jglv3h/top_10_bioprocess